{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T03:51:40Z","timestamp":1782186700661,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10620-025-09044-5","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T12:53:51Z","timestamp":1745067231000},"page":"2843-2851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Obeticholic Acid vs Fibrates as Second-Line Therapy for Primary Biliary Cholangitis: Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"70","author":[{"given":"Eliabe S.","family":"Abreu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Henrique","family":"Reginato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Ferreira Jasmineiro","family":"Pitanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Neves","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Antoine","family":"Soret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Corpechot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Grossi Lopes","family":"Can\u00e7ado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,19]]},"reference":[{"key":"9044_CR1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","volume":"17","author":"AF Gulamhusein","year":"2020","unstructured":"Gulamhusein AF, Hirschfield GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat. Rev. Gastroenterol. Hepatol. 2020;17:93\u2013110. https:\/\/doi.org\/10.1038\/s41575-019-0226-7.","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"9044_CR2","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1111\/jgh.15329","volume":"36","author":"T Lv","year":"2021","unstructured":"Lv T, Chen S, Li M, Zhang D, Kong Y, Jia J. Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis. J. Gastroenterol. Hepatol. 2021;36:1423\u20131434. https:\/\/doi.org\/10.1111\/jgh.15329.","journal-title":"J. Gastroenterol. Hepatol."},{"key":"9044_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000179","volume":"7","author":"J Trivella","year":"2023","unstructured":"Trivella J, John BV, Levy C. Primary biliary cholangitis: Epidemiology, prognosis, and treatment. Hepatol. Commun. 2023;7:e0179. https:\/\/doi.org\/10.1097\/HC9.0000000000000179.","journal-title":"Hepatol. Commun."},{"key":"9044_CR4","doi-asserted-by":"publisher","first-page":"CD000551","DOI":"10.1002\/14651858.CD000551.pub3","volume":"12","author":"JS Rudic","year":"2012","unstructured":"Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst. Rev. 2012;12:CD000551. https:\/\/doi.org\/10.1002\/14651858.CD000551.pub3.","journal-title":"Cochrane Database Syst. Rev."},{"key":"9044_CR5","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","volume":"130","author":"A Par\u00e9s","year":"2006","unstructured":"Par\u00e9s A, Caballer\u00eda L, Rod\u00e9s J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006;130:715\u2013720. https:\/\/doi.org\/10.1053\/j.gastro.2005.12.029.","journal-title":"Gastroenterology"},{"key":"9044_CR6","doi-asserted-by":"publisher","first-page":"11525","DOI":"10.1038\/s41598-019-47890-2","volume":"9","author":"H-U Marschall","year":"2019","unstructured":"Marschall H-U et al. Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort. Sci. Rep. 2019;9:11525. https:\/\/doi.org\/10.1038\/s41598-019-47890-2.","journal-title":"Sci. Rep."},{"key":"9044_CR7","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","volume":"115","author":"CF Murillo Perez","year":"2020","unstructured":"Murillo Perez CF et al. Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. Am. J. Gastroenterol. 2020;115:1066\u20131074. https:\/\/doi.org\/10.14309\/ajg.0000000000000557.","journal-title":"Am. J. Gastroenterol."},{"key":"9044_CR8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens F et al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N. Engl. J. Med. 2016;375:631\u2013643. https:\/\/doi.org\/10.1056\/NEJMoa1509840.","journal-title":"N. Engl. J. Med."},{"key":"9044_CR9","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","volume":"378","author":"C Corpechot","year":"2018","unstructured":"Corpechot C et al. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. N. Engl. J. Med. 2018;378:2171\u20132181. https:\/\/doi.org\/10.1056\/NEJMoa1714519.","journal-title":"N. Engl. J. Med."},{"key":"9044_CR10","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.cgh.2022.07.038","volume":"21","author":"N Abbas","year":"2023","unstructured":"Abbas N et al. UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis. Clin. Gastroenterol. Hepatol. 2023;21:1561-1570.e13. https:\/\/doi.org\/10.1016\/j.cgh.2022.07.038.","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"9044_CR11","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.14309\/ajg.0000000000001343","volume":"116","author":"A Reig","year":"2021","unstructured":"Reig A et al. Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study. Am. J. Gastroenterol. 2021;116:2250\u20132257. https:\/\/doi.org\/10.14309\/ajg.0000000000001343.","journal-title":"Am. J. Gastroenterol."},{"key":"9044_CR12","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3390\/jcm10051061","volume":"10","author":"A-CB Wilde","year":"2021","unstructured":"Wilde A-CB et al. Real-World Clinical Management of Patients with Primary Biliary Cholangitis\u2014A Retrospective Multicenter Study from Germany. J. Clin. Med. 2021;10:1061. https:\/\/doi.org\/10.3390\/jcm10051061.","journal-title":"J. Clin. Med."},{"key":"9044_CR13","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/apt.16336","volume":"53","author":"P Soret","year":"2021","unstructured":"Soret P et al. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis. Aliment. Pharmacol. Ther. 2021;53:1138\u20131146. https:\/\/doi.org\/10.1111\/apt.16336.","journal-title":"Aliment. Pharmacol. Ther."},{"key":"9044_CR14","doi-asserted-by":"publisher","unstructured":"J. A. Sterne et al., \u2018ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions\u2019, BMJ, p. i4919, Oct. 2016, https:\/\/doi.org\/10.1136\/bmj.i4919.","DOI":"10.1136\/bmj.i4919"},{"key":"9044_CR15","doi-asserted-by":"publisher","unstructured":"\u2018Grading quality of evidence and strength of recommendations\u2019, BMJ, vol. 328, no. 7454, p. 1490. https:\/\/doi.org\/10.1136\/bmj.328.7454.1490.","DOI":"10.1136\/bmj.328.7454.1490"},{"key":"9044_CR16","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/sim.1761","volume":"23","author":"MJ Sweeting","year":"2004","unstructured":"Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat. Med. 2004;23:1351\u20131375. https:\/\/doi.org\/10.1002\/sim.1761.","journal-title":"Stat. Med."},{"key":"9044_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med. Res. Methodol. 2014;14:135. https:\/\/doi.org\/10.1186\/1471-2288-14-135.","journal-title":"BMC Med. Res. Methodol."},{"key":"9044_CR18","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2018","unstructured":"Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat. Methods Med. Res. 2018;27:1785\u20131805. https:\/\/doi.org\/10.1177\/0962280216669183.","journal-title":"Stat. Methods Med. Res."},{"key":"9044_CR19","unstructured":"\u2018Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023)\u2019. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). [Online]. Available: www.training.cochrane.org\/handbook"},{"key":"9044_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"9044_CR21","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","volume":"55","author":"C Corpechot","year":"2011","unstructured":"Corpechot C, Chazouill\u00e8res O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J. Hepatol. 2011;55:1361\u20131367. https:\/\/doi.org\/10.1016\/j.jhep.2011.02.031.","journal-title":"J. Hepatol."},{"key":"9044_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/HEP.0000000000000529","volume":"79","author":"C Corpechot","year":"2024","unstructured":"Corpechot C et al. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? Hepatol. Baltim. Md 2024;79:39\u201348. https:\/\/doi.org\/10.1097\/HEP.0000000000000529.","journal-title":"Hepatol. Baltim. Md"},{"key":"9044_CR23","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMoa2312100","volume":"390","author":"GM Hirschfield","year":"2024","unstructured":"Hirschfield GM et al. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. N. Engl. J. Med. 2024;390:783\u2013794. https:\/\/doi.org\/10.1056\/NEJMoa2312100.","journal-title":"N. Engl. J. Med."},{"key":"9044_CR24","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/hepr.13747","volume":"52","author":"M Yamaguchi","year":"2022","unstructured":"Yamaguchi M, Asano T, Arisaka T, Mashima H, Irisawa A, Tamano M. Effects of pemafibrate on primary biliary cholangitis with dyslipidemia. Hepatol. Res. Off. J. Jpn. Soc. Hepatol. 2022;52:522\u2013531. https:\/\/doi.org\/10.1111\/hepr.13747.","journal-title":"Hepatol. Res. Off. J. Jpn. Soc. Hepatol."},{"key":"9044_CR25","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2306185","volume":"390","author":"KV Kowdley","year":"2024","unstructured":"Kowdley KV et al. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. N. Engl. J. Med. 2024;390:795\u2013805. https:\/\/doi.org\/10.1056\/NEJMoa2306185.","journal-title":"N. Engl. J. Med."},{"key":"9044_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/apt.16181","volume":"53","author":"E Gomez","year":"2021","unstructured":"Gomez E et al. Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid. Aliment. Pharmacol. Ther. 2021;53:519\u2013530. https:\/\/doi.org\/10.1111\/apt.16181.","journal-title":"Aliment. Pharmacol. Ther."},{"key":"9044_CR27","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/hep4.1518","volume":"4","author":"SB Roberts","year":"2020","unstructured":"Roberts SB et al. Real-World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis. Hepatol. Commun. 2020;4:1332\u20131345. https:\/\/doi.org\/10.1002\/hep4.1518.","journal-title":"Hepatol. Commun."},{"key":"9044_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100248","volume":"3","author":"D D\u2019Amato","year":"2021","unstructured":"D\u2019Amato D et al. Real-world experience with obeticholic acid in patients with primary biliary cholangitis. JHEP Rep. Innov. Hepatol. 2021;3:100248. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100248.","journal-title":"JHEP Rep. Innov. Hepatol."},{"key":"9044_CR29","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/hep.30552","volume":"70","author":"A Honda","year":"2019","unstructured":"Honda A et al. Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis. Hepatol. Baltim. Md 2019;70:2035\u20132046. https:\/\/doi.org\/10.1002\/hep.30552.","journal-title":"Hepatol. Baltim. Md"},{"key":"9044_CR30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jhep.2021.04.010","volume":"75","author":"A Tanaka","year":"2021","unstructured":"Tanaka A et al. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. J. Hepatol. 2021;75:565\u2013571. https:\/\/doi.org\/10.1016\/j.jhep.2021.04.010.","journal-title":"J. Hepatol."},{"key":"9044_CR31","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1002\/hep4.2103","volume":"6","author":"D Ding","year":"2022","unstructured":"Ding D et al. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid. Hepatol. Commun. 2022;6:3487\u20133495. https:\/\/doi.org\/10.1002\/hep4.2103.","journal-title":"Hepatol. Commun."},{"key":"9044_CR32","doi-asserted-by":"publisher","first-page":"204062232211141","DOI":"10.1177\/20406223221114198","volume":"13","author":"C Li","year":"2022","unstructured":"Li C et al. A randomized, controlled trial on fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid. Ther. Adv. Chronic Dis. 2022;13:20406223221114200. https:\/\/doi.org\/10.1177\/20406223221114198.","journal-title":"Ther. Adv. Chronic Dis."},{"key":"9044_CR33","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1002\/hep.31613","volume":"73","author":"L Smets","year":"2021","unstructured":"Smets L, Verbeek J, Korf H, Van Der Merwe S, Nevens F. Improved Markers of Cholestatic Liver Injury in Patients With Primary Biliary Cholangitis Treated With Obeticholic Acid and Bezafibrate. Hepatology 2021;73:2598\u20132600. https:\/\/doi.org\/10.1002\/hep.31613.","journal-title":"Hepatology"},{"key":"9044_CR34","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1111\/apt.18004","volume":"59","author":"E G\u00f3mez","year":"2024","unstructured":"G\u00f3mez E et al. Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice. Aliment. Pharmacol. Ther. 2024;59:1604\u20131615. https:\/\/doi.org\/10.1111\/apt.18004.","journal-title":"Aliment. Pharmacol. Ther."},{"key":"9044_CR35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1210\/me.2002-0120","volume":"17","author":"I Pineda Torra","year":"2003","unstructured":"Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart J-C, Staels B. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol. Endocrinol. Baltim. Md. 2003;17:259\u2013272. https:\/\/doi.org\/10.1210\/me.2002-0120.","journal-title":"Mol. Endocrinol. Baltim. Md."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09044-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-09044-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09044-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T06:47:07Z","timestamp":1755672427000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-09044-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,19]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["9044"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-09044-5","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,19]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Corpechot reports receiving research grants from Arrow and Intercept France, consulting fees from Intercept France, Advanz, Cymabay, Ipsen, Genkyotex, GlaxoSmithKline France, and Inventiva Pharma, and speaker fees from Intercept France, Echosens, Gilead and GlaxoSmithKline France. Dr. Can\u00e7ado reports receiving a research grant from IPSEN.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}